Fact Sheet for Healthcare Providers: New York SARS-CoV Microsphere Immunoassay for Antibody Detection – Wadsworth Center

Source: U.S. Food and Drug Administration (FDA). Published: 4/30/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the New York SARS-CoV Microsphere Immunoassay for Antibody Detection test, which received an Emergency Use Authorization from the Food and Drug Administration on April 30, 2020. The New York SARS-CoV Microsphere Immunoassay for Antibody Detection test is authorized for the detection of total antibody (IgG, IgM, and IgA) to SARS-CoV-2 in human serum. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news